LinkedIn Profile

Access Endocyte historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
nasdaq:ecyt 1120203 Dec 12th, 2019 12:00AM Endocyte 2.5K 62.00 Open Pharmaceuticals Dec 12th, 2019 01:38PM Dec 12th, 2019 01:38PM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, Companion Imaging Open Purdue Research Park, 3000 Kent Avenue West Lafayette IN US 47906 Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Dec 11th, 2019 12:00AM Endocyte 2.5K 62.00 Open Pharmaceuticals Dec 11th, 2019 09:16AM Dec 11th, 2019 09:16AM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, Companion Imaging Open Purdue Research Park, 3000 Kent Avenue West Lafayette IN US 47906 Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Dec 10th, 2019 12:00AM Endocyte 2.5K 62.00 Open Pharmaceuticals Dec 10th, 2019 02:11PM Dec 10th, 2019 02:11PM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, Companion Imaging Open Purdue Research Park, 3000 Kent Avenue West Lafayette IN US 47906 Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Dec 9th, 2019 12:00AM Endocyte 2.5K 62.00 Open Pharmaceuticals Dec 9th, 2019 12:40PM Dec 9th, 2019 12:40PM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, Companion Imaging Open Purdue Research Park, 3000 Kent Avenue West Lafayette IN US 47906 Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Dec 8th, 2019 12:00AM Endocyte 2.5K 62.00 Open Pharmaceuticals Dec 8th, 2019 12:00PM Dec 8th, 2019 12:00PM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, Companion Imaging Open Purdue Research Park, 3000 Kent Avenue West Lafayette IN US 47906 Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Dec 7th, 2019 12:00AM Endocyte 2.5K 63.00 Open Pharmaceuticals Dec 6th, 2019 09:21PM Dec 6th, 2019 09:21PM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, Companion Imaging Open Purdue Research Park, 3000 Kent Avenue West Lafayette IN US 47906 Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Dec 6th, 2019 12:00AM Endocyte 2.5K 63.00 Open Pharmaceuticals Dec 6th, 2019 10:09AM Dec 6th, 2019 10:09AM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, Companion Imaging Open Purdue Research Park, 3000 Kent Avenue West Lafayette IN US 47906 Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Dec 5th, 2019 12:00AM Endocyte 2.5K 63.00 Open Pharmaceuticals Dec 4th, 2019 09:21PM Dec 4th, 2019 09:21PM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, Companion Imaging Open Purdue Research Park, 3000 Kent Avenue West Lafayette IN US 47906 Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Dec 4th, 2019 12:00AM Endocyte 2.5K 63.00 Open Pharmaceuticals Dec 4th, 2019 11:00AM Dec 4th, 2019 11:00AM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, Companion Imaging Open Purdue Research Park, 3000 Kent Avenue West Lafayette IN US 47906 Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Dec 3rd, 2019 12:00AM Endocyte 2.5K 63.00 Open Pharmaceuticals Dec 3rd, 2019 12:24PM Dec 3rd, 2019 12:24PM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, Companion Imaging Open Purdue Research Park, 3000 Kent Avenue West Lafayette IN US 47906 Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.